To transport a hunger-suppressing molecule to the gut as a treatment for obesity, researchers at Vanderbilt University have put bacteria to work. The bacteria become lodged in the digestive system and release the lipid for up to a year at a time, altering the gut microbiome to stave off weight-related problems like diabetes and heart disease.
Startup MHB Labs announced the receipt of $1.1 million in seed financing from Romulus Capital and other angel investors in support of its drug delivery technology for convenient administration of a commercially available but little-used medication that could have applications in the men's health space.
The U.S. Food and Drug Administration has placed a hold on enrollment in the ongoing U.S. pivotal trial for the EndoBarrier. The device is a gastric liner from GI Dynamics that is intended to inhibit the absorption of nutrients, thereby providing weight loss and addressing obesity and Type 2 diabetes.
The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.
The FDA isn't happy with Orexigen, which put out some early positive cardio data for obesity drug Contrave Tuesday. The way the FDA sees it, the data were too early, and it's now asking Orexigen for a second outcomes study. But meanwhile, the new stats have changed some analysts' minds about Contrave's safety profile--something that could give it a leg up in a crowded market going forward.
Two different teams at Columbia and Harvard have independently created neurons out of iPS cells that regulate appetite, offering a new model for investigators who are studying new weight drugs and various elements of weight control.
Investigators at Queen Mary University of London say that by regulating the length of primary cilia on stem cells they could prevent them from turning into fat cells--a possible new direction in obesity research.
Shifting focus from the hypothalamus to the amygdala, investigators at Boston University say that an injection of a peptide and hormone reduced appetite in an experimental model, pointing to a new approach to treating obesity and binge eating.
USGI Medical expects that its latest infusion of $19.5 million in cash and debt will enable it to complete a U.S. pivotal trial and to submit for FDA approval. The pivotal trial is currently in the follow-up phase; the financing will also enable a crossover study of patients who previously had received sham treatment in the trial.
Novo Nordisk's obesity therapy Saxenda is on a roll. Just over a month after snagging FDA approval, the drug scored a positive recommendation on Thursday from Europe's Committee for Medicinal Products for Human Use (CHMP). But by the time it gets to the regulatory finish line, the med may have some competition on the continent.